This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.
Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%
by Zacks Equity Research
Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.
CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
by Zacks Equity Research
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
by Zacks Equity Research
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.
STERIS (STE) Set to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.
Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth
by Zacks Equity Research
Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.
Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.
How Much Upside is Left in Acadia (ACAD)? Wall Street Analysts Think 38.62%
by Zacks Equity Research
The consensus price target hints at a 38.6% upside potential for Acadia (ACAD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.
Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.